WS #14751
Nanexa shares rocketed 114% following a $1.3 billion licensing deal with Novo Nordisk, signaling strong investor appetite for innovative pharmaceutical partnerships. This deal highlights the continued M&A and licensing activity in the biotech sector, driven by the demand for novel weight-loss and metabolic treatments. The move underscores the financial strength of large-cap pharma companies investing in smaller, innovative firms.
Pharma & Biotech Deals
Nanexa shares rocketed 114% following a $1.3 billion licensing deal with Novo Nordisk, signaling strong investor appetite for innovative pharmaceutical partnerships. This deal highlights the continued M&A and licensing activity in the biotech sector, driven by the demand for novel weight-loss and metabolic treatments. The move underscores the financial strength of large-cap pharma companies investing in smaller, innovative firms.